407 related articles for article (PubMed ID: 10617681)
1. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.
Fitzgerald LW; Burn TC; Brown BS; Patterson JP; Corjay MH; Valentine PA; Sun JH; Link JR; Abbaszade I; Hollis JM; Largent BL; Hartig PR; Hollis GF; Meunier PC; Robichaud AJ; Robertson DW
Mol Pharmacol; 2000 Jan; 57(1):75-81. PubMed ID: 10617681
[TBL] [Abstract][Full Text] [Related]
2. Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor.
Setola V; Dukat M; Glennon RA; Roth BL
Mol Pharmacol; 2005 Jul; 68(1):20-33. PubMed ID: 15831837
[TBL] [Abstract][Full Text] [Related]
3. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.
Setola V; Hufeisen SJ; Grande-Allen KJ; Vesely I; Glennon RA; Blough B; Rothman RB; Roth BL
Mol Pharmacol; 2003 Jun; 63(6):1223-9. PubMed ID: 12761331
[TBL] [Abstract][Full Text] [Related]
4. The fenfluramine metabolite (+)-norfenfluramine is vasoactive.
Ni W; Li MW; Thakali K; Fink GD; Watts SW
J Pharmacol Exp Ther; 2004 May; 309(2):845-52. PubMed ID: 14752059
[TBL] [Abstract][Full Text] [Related]
5. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
Rothman RB; Baumann MH; Savage JE; Rauser L; McBride A; Hufeisen SJ; Roth BL
Circulation; 2000 Dec; 102(23):2836-41. PubMed ID: 11104741
[TBL] [Abstract][Full Text] [Related]
6. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity.
Miller KJ
Mol Interv; 2005 Oct; 5(5):282-91. PubMed ID: 16249524
[TBL] [Abstract][Full Text] [Related]
7. Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves.
Roy A; Brand NJ; Yacoub MH
J Heart Valve Dis; 2000 Mar; 9(2):256-60; discussion 260-1. PubMed ID: 10772044
[TBL] [Abstract][Full Text] [Related]
8. The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease.
Kekewska A; Hübner H; Gmeiner P; Pertz HH
J Pharmacol Exp Ther; 2011 Jul; 338(1):381-91. PubMed ID: 21518772
[TBL] [Abstract][Full Text] [Related]
9. Serotonergic drugs and valvular heart disease.
Rothman RB; Baumann MH
Expert Opin Drug Saf; 2009 May; 8(3):317-29. PubMed ID: 19505264
[TBL] [Abstract][Full Text] [Related]
10. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.
Gobert A; Rivet JM; Lejeune F; Newman-Tancredi A; Adhumeau-Auclair A; Nicolas JP; Cistarelli L; Melon C; Millan MJ
Synapse; 2000 Jun; 36(3):205-21. PubMed ID: 10819900
[TBL] [Abstract][Full Text] [Related]
11. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects.
Rajamannan NM; Caplice N; Anthikad F; Sebo TJ; Orszulak TA; Edwards WD; Tajik J; Schwartz RS
J Heart Valve Dis; 2001 Nov; 10(6):827-31. PubMed ID: 11767194
[TBL] [Abstract][Full Text] [Related]
12. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies.
Sachdev M; Miller WC; Ryan T; Jollis JG
Am Heart J; 2002 Dec; 144(6):1065-73. PubMed ID: 12486432
[TBL] [Abstract][Full Text] [Related]
13. [Appetite suppressants and heart valve disorders].
Adams C; Cohen A
Arch Mal Coeur Vaiss; 1999 Sep; 92(9):1213-9. PubMed ID: 10533670
[TBL] [Abstract][Full Text] [Related]
14. Regulation of serotonin-2C receptor G-protein coupling by RNA editing.
Burns CM; Chu H; Rueter SM; Hutchinson LK; Canton H; Sanders-Bush E; Emeson RB
Nature; 1997 May; 387(6630):303-8. PubMed ID: 9153397
[TBL] [Abstract][Full Text] [Related]
15. Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
Egan C; Grinde E; Dupre A; Roth BL; Hake M; Teitler M; Herrick-Davis K
Synapse; 2000 Feb; 35(2):144-50. PubMed ID: 10611640
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic and adverse actions of serotonin transporter substrates.
Rothman RB; Baumann MH
Pharmacol Ther; 2002 Jul; 95(1):73-88. PubMed ID: 12163129
[TBL] [Abstract][Full Text] [Related]
17. 5-HT4 and 5-HT2 receptors antagonistically influence gap junctional coupling between rat auricular myocytes.
Derangeon M; Bozon V; Defamie N; Peineau N; Bourmeyster N; Sarrouilhe D; Argibay JA; Hervé JC
J Mol Cell Cardiol; 2010 Jan; 48(1):220-9. PubMed ID: 19615378
[TBL] [Abstract][Full Text] [Related]
18. WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity.
Dunlop J; Sabb AL; Mazandarani H; Zhang J; Kalgaonker S; Shukhina E; Sukoff S; Vogel RL; Stack G; Schechter L; Harrison BL; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2005 May; 313(2):862-9. PubMed ID: 15705738
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects of benfluorex on heart valves and pulmonary circulation.
Szymanski C; Andréjak M; Peltier M; Maréchaux S; Tribouilloy C
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):679-86. PubMed ID: 24817577
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors.
Görnemann T; Hübner H; Gmeiner P; Horowski R; Latté KP; Flieger M; Pertz HH
J Pharmacol Exp Ther; 2008 Mar; 324(3):1136-45. PubMed ID: 18096760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
